We're building a better ClinicalTrials.gov. Check it out and tell us what you think!

Key Record Dates

ClinicalTrials.gov Identifier: NCT03220477
Brief Title: Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

First Submitted : July 14, 2017
First Submitted that Met QC Criteria : July 14, 2017
First Posted : July 18, 2017

Last Update Submitted that Met QC Criteria : December 13, 2022
Last Update Posted : December 15, 2022